Biology of Blood and Marrow Transplantation
Volume 15, Issue 9 , Pages 1100-1107 , September 2009

Hypertension and Diabetes Mellitus in Adult and Pediatric Survivors of Allogeneic Hematopoietic Cell Transplantation

  • Navneet S. Majhail, MD, MS

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota
    • Corresponding Author InformationCorrespondence and reprint requests: Navneet Majhail, MD, MS, University of Minnesota, Division of Hematology, Oncology and Transplantation, 420 Delaware Street SE, MMC 480, Minneapolis, MN 55455.
    • ,
  • Tejo R. Challa, MD

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota
    • ,
  • Daniel A. Mulrooney, MD, MS

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota
    • ,
  • K. Scott Baker, MD, MS

      Affiliations

    • Survivorship Program, Fred Hutchinson Cancer Research Center, Seattle, Washington
    • ,
  • Linda J. Burns, MD

      Affiliations

    • Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota

Received 2 March 2009 ,Accepted 12 May 2009.

  • Image Result

    Prevalence of hypertension and diabetes within the first 2 years post-HCT by prednisone (or equivalent) exposure. Our study cohort comprised of patients who had survived for >1 year after transplantat

    Prevalence of hypertension and diabetes within the first 2 years post-HCT by prednisone (or equivalent) exposure. Our study cohort comprised of patients who had survived for >1 year after transplantation.

  • Image Result
    Prevalence of persistent hypertension and diabetes at 2-years post-HCT by prednisone (or equivalent) exposure. Our study cohort comprised of patients who had survived for >1 year after transplantation

    Prevalence of persistent hypertension and diabetes at 2-years post-HCT by prednisone (or equivalent) exposure. Our study cohort comprised of patients who had survived for >1 year after transplantation.

 Financial disclosure: See Acknowledgments on page 1106.

PII: S1083-8791(09)00249-3

doi: 10.1016/j.bbmt.2009.05.010

Biology of Blood and Marrow Transplantation
Volume 15, Issue 9 , Pages 1100-1107 , September 2009

Article Tools

* Image Usage & Resolution